Difference between revisions of "Peginterferon alfa-2b (Sylatron)"
(Created page with "==General information== Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially med...") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/peginterferonalfa- | + | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/peginterferonalfa-2b.pdf Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 20:35, 22 February 2012
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to Interferon alfa-2b (Intron-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Peginterferon alfa-2b (PegIntron) patient drug information (Chemocare)[3]
- Peginterferon alfa-2b (PegIntron) patient drug information (UpToDate)[4]